Mitoxantrone
Pediatric AML
Princess Maxima Center for Pediatric OncologySmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Pediatric AML cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Idarubicine Joanna Yi | Phase 3 | BBB |
Cladribine Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2/3 | B |
RH-ARG1-PEG-5,000 MW University of Birmingham | Phase 1/2 | CCC |
PREDNISOLONE SODIUM SUCCINATE Joanna Yi | Early Phase 1 | C |
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) Joanna Yi | Early Phase 1 | C |
Epirubicin Joanna Yi | Early Phase 1 | C |
Pembrolizumab Joanna Yi | Early Phase 1 | C |
Same molecule, other indications
Mitoxantrone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →